CClinicalTrials.gg
CompletedNCT05144724VOLTUpdated Jan 13, 2026

Volume Targeted Mask Ventilation Versus Pressure Ventilation in Preterm Infants

An interventional study of Volume targeted ventilation and Pressure targeted ventilation in Neonatal Respiratory Distress, sponsored by University of Alberta. Completed at 1 site in Canada. Open to participants aged 0 Minutes to 1 Minute. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by University of Alberta · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
0 Minutes to 1 Minute
Sex
All
01

Study summary

This is a pilot trial to assess the feasibility of volume Targeted Ventilation in the Delivery Room.

Preterm infants will be randomized to pressure guided or volume targeted ventilation during respiratory support in the delivery room

02

Conditions studied

  • Neonatal Respiratory Distress

Browse trials for

03

In context

Pulmonary Atelectasis

301 studies on the registry are indexed under Pulmonary Atelectasis; 80 are open to participants now.

This study's enrollment of 52 is below the median of 61 across 222 interventional studies indexed under Pulmonary Atelectasis.

Browse Pulmonary Atelectasis studies →

Lead sponsor

University of Alberta is the lead sponsor of 800 studies on the registry; 168 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Minutes to 1 Minute
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Born between 23+0/7 to 28+6/7 weeks' gestation
  • Considered suitable for full resuscitation, i.e., no parental request or antenatal decision to forego resuscitation
  • Informed parental consent

Exclusion criteria

Exclusion Criteria:

  • Major congenital or chromosomal malformation
  • Conditions that might have an adverse effect on breathing or ventilation (e.g., high risk for lung hypoplasia, congenital diaphragmatic hernia)
  • Congenital heart disease requiring intervention in the neonatal period
  • Hydrops requiring intervention in the neonatal period
  • Neonatal resuscitation initiated before NICU team arrival
  • Infants who are born outside of study center and transported to center after delivery
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Volume Targeted Ventilation

    Positive pressure ventilation will be provided using a set tidal volume

    Procedure: Volume targeted ventilation

  • Active comparator
    Pressure guided Ventilation

    Positive pressure ventilation will be provided using a set peak inflation pressure

    Procedure: Pressure targeted ventilation

Interventions

  • ProcedureVolume targeted ventilation

    Positive pressure ventilation will be provided using a set tidal volume

  • ProcedurePressure targeted ventilation

    Positive pressure ventilation will be provided using a set peak inflation pressure

06

What researchers measure

Primary outcomes

  1. Percentage of of eligible participants (=infants requiring PPV) who have the intervention performed correctly without protocol deviation (=cross over to control group when randomized to VTV-group)

    Percentage of Participants who have received allocated treatment

    Time frame: Through study completion (total 18 months)

Secondary outcomes

  1. Number of participants with mortality

    Infants who died during NICU admission - all-cause in-hospital

    Time frame: up to 6 months of NICU admission

  2. Number of participants with severe brain injury on cranial ultrasound

    Severe grade 3 and 4 intraventricular or intraparenchymal hemorrhage according to Papile, periventricular leukomalacia, or ventriculomegaly based on neuroimaging studies (timing and frequency of imaging based on local site practices)

    Time frame: up to 6 months of NICU admission

  3. Number of participants with severe retinopathy of prematurity (stage 3 or higher)

    Defined in the International Classification of ROP, and/or ROP treated with laser, cryotherapy, or intraocular injection therap

    Time frame: up to 6 months of NICU admission

  4. Number of participants with bronchopulmonary dysplasia at 36 weeks corrected age

    Defined as receiving any supplemental oxygen or any form of respiratory support (including invasive mechanical ventilation, non-invasive ventilation with continuous positive airway pressure, nasal intermittent positive pressure ventilation, or high-flow nasal canula)

    Time frame: At 36 weeks corrected age

  5. Number of participants with Bronchopulmonary dysplasia at 40 weeks corrected age

    Defined as receiving any supplemental oxygen or any form of respiratory support (including invasive mechanical ventilation, non-invasive ventilation with continuous positive airway pressure, nasal intermittent positive pressure ventilation, or high-flow nasal canula)

    Time frame: At 40 weeks corrected age

  6. Total duration of mechanical ventilation via an endotracheal tube in days

    Count of days in were an endotracheal tube was placed and the infant was mechanical ventilation

    Time frame: Days during NICU admission (up to 6 months)

  7. Number of participants discharge home on oxygen

    Infants being discharged home with oxygen

    Time frame: At time of NICU discharge (with 6 moths from birth)

  8. Duration of any respiratory support in days

    Defined as invasive mechanical ventilation, non-invasive ventilation with continuous positive airway pressure, nasal intermittent positive pressure ventilation, or non-invasive neural assist ventilation or non-invasive high frequency ventilation, or high-flow nasal cannula) in days

    Time frame: Days during NICU admission (up to 6 months)

  9. Duration of supplemental oxygen in days

    Count of days in were the infant received supplemental oxygen

    Time frame: Days during NICU admission (up to 6 months)

  10. Length of hospital stay in days

    Defined as number of days from birth to discharge

    Time frame: Number of days from birth to discharge (up to 6 months)

  11. Rate of intubation in the delivery room

    Infants who were intubated in the delivery room at birth

    Time frame: within 60min after birth

  12. Rate of chest compression in the delivery room

    Infants who received chest compression in the delivery room at birth

    Time frame: within 60min after birth

  13. Rate of pneumothorax

    Diagnosed by chest x-ray or lung ultrasound) and interventions (e.g., needle drainage or chest drain)

    Time frame: up to 6 months of NICU admission

  14. Number of participants with necrotizing enterocolitis

    Defined as modified Bell's criteria stage 2 or greater

    Time frame: up to 6 months of NICU admission

  15. Duration of positive pressure ventilation at birth in days

    Infants who received positive pressure ventilation in the delivery room at birth

    Time frame: within the first 10 min after birth

Other outcomes

  1. Resuscitators subjective workload performing mask ventilation

    Es evaluated by Surgery Task Load Index (SURG-TLX)-questionnaire.

    Time frame: within the first 10 min after birth

  2. Resuscitators qualitative feedback on using VTV-PPV in the delivery room

    Provided through free text responses

    Time frame: within the first 10 min after birth

07

Study locations

1 site
  • Royal Alexandra Hospital
    Edmonton, Alberta T5H 3V9, Canada
08

References and documents

Publications

  • Law BHY, Yaskina M, Davis PG, Polglase G, Dunn M, Mukerji A, Schmolzer GM. Study protocol for the volume targeted mask ventilation versus pressure ventilation in preterm infants-the VOLT-trial. Front Pediatr. 2026 Jan 6;13:1743460. doi: 10.3389/fped.2025.1743460. eCollection 2025. PubMed 41567425 ↗
  • Bharadwaj U, Kainth D, Sankar J. Refining Ventilation During Neonatal Resuscitation Using Ventilator: Time for a Well-Designed Clinical Study! Indian J Pediatr. 2024 Oct;91(10):997-998. doi: 10.1007/s12098-024-05154-6. Epub 2024 May 10. No abstract available. PubMed 38727883 ↗

Study documents

  • Study protocol · Jan 6, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — The protocol will be published in an open access journal and data can be requested from the principal investigator

Supporting information: Study protocol, Icf

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05144724
Lead sponsor
University of Alberta
Responsible party
Sponsor
First posted
Dec 3, 2021
Start date
Oct 1, 2024
Primary completion
Oct 30, 2025
Completion
Dec 17, 2025
Last update
Jan 13, 2026

Study contacts

Georg Schmölzer, MD, PhD
principal investigator · University of Alberta

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion